Cardiovascular sales set to grow 11% a year as new leaders emerge
The branded cardiovascular market is forecast to grow at 11% a year between 2025 and 2032, well ahead of the 7% forecast for prescription drugs overall. That growth is fueled through new products across novel mechanisms and modalities, and the 2032 ranking of leading companies will look very different from today’s. Scrip’s Jessica Merrill and […]
Meet the Team: Brian Bock
We’re always delighted to welcome new people into the fold at Evaluate, particularly when they bring a new perspective on a critical part of the life sciences market. Today’s subject of Meet the Team is Brian Bock, Leader of Strategic Broker Partnerships for Norstella. With a resume that features Morgan Stanley and Deutsche Bank, Brian […]
Evaluate Leaders Forum: Pipeline productivity, over breakfast, in London
Most people in pharma are aware that R&D costs are rising, both in dollar terms and in development timelines. But the reaction is less well-known: risk is being front loaded to Phase I and relative success rates have fallen by around 15%. More promisingly, the average launch fares better today, now sitting at $1.6bn after […]
Inside the $200 Billion Race for the Next Immunology Blockbusters
Immunology is one of pharma’s most valuable and fastest-growing therapy areas, with forecast compound annual growth of over 9% and anticipated combined sales of $200 billion by 2032. Multi-indication immunology blockbusters dominate the landscape across more than 100 autoimmune and inflammatory conditions, many sharing underlying biological mechanisms. That “pipeline-in-a-product” profile appeals strongly to companies managing […]
Why Your Pharma Forecast Model is Failing the People Who Use it
Pharma forecasting models are critical to your planning processes. They’re also complex beasts which, if not fully understood by the people using them, can become distrusted and frustrating. I caught up with Abigail Spedding, Implementation Director at J+D Forecasting, to talk about what separates a forecast model that drives decisions from one that gets sidelined. […]
CNS Dealmaking has Become More Selective
CNS drug development has had a significant revival. Anti-amyloid agents like Leqembi have shown meaningful slowing of Alzheimer’s progression, and Cobenfy’s 2024 approval marked the first non-dopaminergic schizophrenia treatment in over 30 years. A therapeutic area that saw multiple big pharma exits just a decade ago is attracting capital again. We cover the full picture […]
Why Your LBE Keeps Drifting From the Plan
Your Latest Best Estimate (LBE) forecast is the perfect partner to your Annual Operating Plan (AOP). Well, they are perfect partners when they work together effectively, which isn’t always – or even usually – the case. To learn more about what teams get wrong and how they can get their LBEs and AOPs working together […]
Turning R&D Benchmarks into Competitor Signals: What We’re Bringing to Pharma CI
Evaluate is at Pharma CI 2026 in Newark, New Jersey, on 16 and 17 September, talking agentic AI, turning R&D benchmarks into competitor signals, and our new competitive intelligence agent, Atlas CI. Pharma CI is just around the corner again – it seems to come around quicker every year! The Evaluate team is heading to […]
What are you Getting Wrong in your Annual Operating Plan?
The Annual Operating Plan (AOP) and the Latest Best Estimate (LBE) are two of the most important forecasting processes a biotech or pharma commercial team runs. They are also among the most misunderstood, usually over how the two should work together. I caught up with Amanda Randall, Senior Director, Implementation at J+D Forecasting, to talk […]
Oncology Dealmaking is Becoming More Surgical
Oncology remains the largest segment in global pharma, accounting for around $241bn in 2025 prescription drug revenues. But portfolio momentum is fragmenting, and the next growth cycle looks materially different from the last one. We address many of the big issues in the oncology space in the new Evaluate Spotlight episode which is available here. […]
